Study

Study population

Characteristics

N

Design Main findings *

Dore et al. 2005 [59]

Systemic RV (TGA) Majority NYHA I
RVEF 42%

29

Multicenter RCT crossover design
Losartan vs. placebo for 15 weeks
No difference in peak VO2, exercise duration or NT-proBNP levels.

Lester et al.
2001 [60]

D-TGA (atrial baffle)       

 

Age > 13 yrs
NYHA < IV
RVEF 48%

7

RCT, crossover design. Losartan vs. placebo for 8 weeks Beneficial effect: ↑exercise time by 18%, ↓ regurgitant volume by 63.5%, ↑ RVEF 6%‡

Robinson et al. 2002 [61]

D-TGA (atrial baffle)

NYHA I
Age 7 to 21 yrs
CI 2.2 L/min/m2

8

Single arm prospective study
Enalapril for 1 year
No difference in exercise duration, peak VO2 or cardiac index

Therrien et al. 2008 [62]

D-TGA (atrial baffle) Mainly NYHA class I
Age > 18 yrs
RVEF 44%

17

Multicenter RCT
Ramipril vs. placebo for 1 year
No difference in RVEF, RV volume or  peak VO2

Hechter et al. 2001 [63]

D-TGA (atrial baffle) Age > 26 yrs
RVEF 47%

26

Retrospective study
ACE-I  from 6 to 126 months
No difference in  peak VO2, exercise duration
*Unless otherwise specified, the results refer to statistically significant findings (p<0.05). The changes reported refer to relative changes in mean effect size or when indicated by ‡ changes in absolute effect size. Abbreviations as in previous tables. TGA indicates transposition of great arteries; TTPG, trans tricuspid pressure gradient
Table 3: Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in RHF.